Healthcare | April 25, 2026
Vision 360 brings academia, industry together to advance ophthalmic therapies
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Targets high-growth eye care expansion push
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Scientists at the forum warned of an increasingly volatile health landscape
The trial also demonstrated significant improvements across multiple secondary endpoints
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
Subscribe To Our Newsletter & Stay Updated
